Wednesday, February 21, 2018
 
 
Company News: Page (1) of 1 - 02/12/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
COA: Analysis Shows New Mexico Hospitals Benefit From Recent Changes In Medicare Payment
All New Mexico Hospitals Will See 2 Percent More in Net Payments from Recent Changes to the Medicare Part B and 340B Drug Discount Programs
(February 12, 2018)

WASHINGTON, Feb. 12, 2018 /PRNewswire-USNewswire/ -- Hospitals in New Mexico, especially those in rural areas, will benefit from recent changes to Medicare prescription drug payments, including changes to a federal program known as the 340B Drug Discount Program.

Community Oncology Alliance (COA) (PRNewsfoto/Community Oncology Alliance)

On average, New Mexico hospitals will see a 2 percent increase—or an additional $6,334,756—in Medicare payments related to the changes.



These findings are included in new research released by Avalere Health, a nonpartisan DC-based firm that analyzes the impact of health policies. The study dispels misinformation being touted by some large, corporate hospitals that the new payment system and changes to the 340B Drug Discount Program would bring drastic cuts to hospital reimbursement and threaten their operations. New Mexico hospitals are estimated to receive more than $318 million in net Medicare payments as a result of the changes in 2018.

Started by Congress in 1992, the 340B program gives certain hospitals and clinics that treat high numbers of uninsured or underinsured patients steep discounts on drugs purchased. The program has grown substantially, morphing into a profit-generating program for most hospitals who can make upwards of 50 percent profits selling drugs purchased at a discount to insured patients. Today, nearly half of all acute care hospitals participate in the 340B program. Recognizing that it is being abused by some hospitals, the government sought to reduce the profit motivation by adjusting the payment rate for drugs purchased through 340B beginning this year.

"Contrary to what the public and Congress is being told, the vast majority of America's hospitals, and in particular rural hospitals, are benefitting from recent Medicare's payment changes," said Ted Okon, executive director of the Community Oncology Alliance (COA) which commissioned the study. "All New Mexico hospitals benefit from the recent 340B and Medicare changes, not just a select few. What's more, consumers will save money in lower drug co-pays, so everyone wins."

Experts from the Centers for Medicare & Medicaid Services (CMS) predict that the changes to 340B payments will save seniors an estimated $320 million in drug copayments nationally in 2018 alone.

Many 340B hospitals have predicted that reductions to the program, which took effect on Jan. 1, would cause them to lose revenue. The Avalere research shows that increases in Medicare Part B payments have more than offset the 340B cuts, with 42 states, including New Mexico, seeing overall payment increases.

"Community oncologists care deeply about the future of 340B, because some hospitals continue to use the program's cost savings as a business strategy to eliminate local clinics," said Barbara L. McAneny, MD, CEO of New Mexico Cancer Care and a member of the COA board. "The Avalere data are clear: New Mexico hospitals aren't going to lose money from Medicare payment adjustments like they said. It's time they started using 340B to help patients the way the program was intended, instead of irreparably harming the backbone of our cancer care system. When local clinics shut down, patients and families suffer."

According to the most recent Community Oncology Alliance Practice Impact Report, New Mexico has seen 12 community oncology clinics close or merge into the hospital setting since 2008. This results in less choice in local cancer care providers and significantly higher costs to patients for the exact same cancer care.

The Avalere analysis comes on the heels of an independent study released last week in the New England Journal of Medicine (NEJM) which found that the 340B program driving consolidation of the nation's cancer care system into the much more expensive hospital system; is associated with hospitals administering more cancer drugs; and has not resulted in any clear expansion care or lower mortality for needy patients.

The Avalere study and methodology are available at https://www.communityoncology.org/20180126_opps-analysis-final/.

About the Community Oncology Alliance: COA is a non-profit organization dedicated to advocating for community oncology practices and, most importantly, the patients they serve. COA is the only organization dedicated solely to independent community oncology where the majority of Americans with cancer are treated. The mission of COA is to ensure that cancer patients receive quality, affordable, and accessible cancer care in their own communities. For more than 15 years, COA has built a national grassroots network of community oncology practices to advocate for public policies that benefit cancer patients. To learn more about COA, visit www.CommunityOncology.org. Follow COA on Twitter at www.twitter.com/oncologyCOA. Follow COA on Facebook at www.facebook.com/CommunityOncologyAlliance

Cision View original content with multimedia:http://www.prnewswire.com/news-releases/coa-analysis-shows-new-mexico-hospitals-benefit-from-recent-changes-in-medicare-payment-300597407.html

SOURCE Community Oncology Alliance

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:England,Science,Medical,Cancer,Business,mexico,england,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • SourceLink Partners with MassMedia Health to Provide Medicare Age-In Data to Healthcare Groups
  • U.S. Nebulizer Market Size Worth $435.5 Million By 2025 | CAGR 6.2%: Grand View Research, Inc.
  • Global Cables and Leads for Medical Equipment Industry
  • Pain Management Devices Market USD 5.81 Billion Revenue At 7.2 % CAGR by 2023; Exclusively Available at MarketResearchFuture.com
  • Ocular Surgery Devices Market By Application, Technology, Product, Region and Forecast 2025 - Credence Research

    Cancer
  • Bolivian Government Invests in State-of-the-art Cancer Care From Elekta
  • QCCA Evolves to Become the First National Clinically Integrated Network in Oncology
  • COA: Analysis Shows Virginia Hospitals Benefit From Recent Changes In Medicare Payment
  • 2018 Global Endometriosis Strategic Business Report - Developing Regions Exhibit Immense Growth Potential
  • Cannabics Pharmaceuticals Hires Chief Data Officer to Address Industry Compliance and Utilization/Analytics Application
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines